Delineating IL-2

Why autoimmune play Delinia lent itself to clean takeout by Celgene

While Celgene Corp. has a history of entering creative deals that enable its smaller partners to retain control over early development, Delinia Inc.’s clinically validated approach to treating autoimmune diseases, paired with preclinical proof-of-concept data, made the start-up ripe for a straightforward takeout.

It didn’t hurt that the biotech received multiple bids.

According to Delinia President and CEO Saurabh Saha, the bellwether can accelerate and broaden the path to market for lead compound DEL106.

DEL106 is a Treg-selective IL-2 receptor agonist designed to selectively activate and expand immunosuppressive Tregs without

Read the full 889 word article

User Sign In